Author(s):
Amit Gupta, Tulika Bhatt, Shikha Chaudhary, Vrinda Prabhakar, Yashaswi Singh
Email(s):
amit.gupta@jammuuniversity.ac.in
DOI:
10.52711/0974-360X.2024.00552 
Address:
Amit Gupta1*, Tulika Bhatt2, Shikha Chaudhary2,Vrinda Prabhakar2, Yashaswi Singh2
1Department of Zoology, University of Jammu, Baba Saheb Ambedkar Road, Tawi, Jammu, Jammu and Kashmir 180006.
2Department of Microbiology and Biotechnology, Graphic Era Deemed to be University, Dehradun.
*Corresponding Author
Published In:
Volume - 17,
Issue - 7,
Year - 2024
ABSTRACT:
Adjuvants are routinely used in vaccines for improving is immunogenicity against various antigens. Although, addition of low molecular weight molecules used as adjuvant may sometimes causing local side effects at the injection site. In general, vaccines may contained several preservatives i.e. thimerosalhaving ethyl mercury which is reported. Alum (also known as aluminium hydroxide or aluminium phosphate) ranks as one of the most commonly employed and effective adjuvants for human consumption. In general, vaccines containing adjuvants may be considered as one of the greatest achievements in the scientific field, having saved millions of people from various infectious diseases. Recently, COVID-19 pandemic is giving some hope for constructing or producing a vaccine containing adjuvant which may be effective and productive to save more lives. Such types of vaccines are totally dependent on long lasting immunity and also protect from various infectious agents.Adjuvants are thus closely linked with or blended into the vaccine antigen with the objective to boost the immunogenicity of the vaccination antigen or to provoke an immune response. This is how this immunity is mostly accomplished. This article will address the adjuvants require for the vaccination antigen to improve its immunogenicity.
Cite this article:
Amit Gupta, Tulika Bhatt, Shikha Chaudhary, Vrinda Prabhakar, Yashaswi Singh. Adjuvants for Antigens in Vaccines: Review. Research Journal of Pharmacy and Technology. 2024; 17(7):3533-0. doi: 10.52711/0974-360X.2024.00552
Cite(Electronic):
Amit Gupta, Tulika Bhatt, Shikha Chaudhary, Vrinda Prabhakar, Yashaswi Singh. Adjuvants for Antigens in Vaccines: Review. Research Journal of Pharmacy and Technology. 2024; 17(7):3533-0. doi: 10.52711/0974-360X.2024.00552 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-7-85
REFERENCES:
1. Nugraheni RW. Yusuf H.Setyawan D. The Design of Liposomal Vaccine Adjuvant. Asian Journal of Pharmacy and Technology. 2017; 7 (4): 234-236. doi.org/10.5958/2231-5713.2017.00035.6.
2. Saha S. Roy A. Bahadur S.Chandrakar S. Choudhury A.Das S. Phytochemicals as Adjuvant in Neoplasia. Asian Journal of Research in Chemistry. 2014; 7(8): 765-770. doi.org/10.5958/0974-4150.
3. Stefano M. Beatrice M. Probiotics as adjuvant therapy in the treatment of Allergic Rhinitis. Research Journal of Pharmacy and Technology. 2023; 16(5): 2393-8. doi.org/10.52711/0974-360X.2023.00394.
4. Kumar SA.Venkatarathanamma V. Naga SV.Nageswara RT.Pavan KK. Kumar SK.Vijayalakshmi A. Anti-arthritic Activity of Annona squamosa Leaves Methanolic Extract on Adjuvant Induced Arthritis in Rats. Research Journal of Pharmacology and Pharmacodynamics 2017; 9(2): 46-56. doi.org/10.52711/0974-360X.2023.00394.
5. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. The Journal of Clinical Investigation 2016; 126: 799–808. doi.org/10.1172/JCI81083
6. Ghimire TR. Benson RA. Garside P. Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunology Letters. 2012; 147: 55–62. doi.org/10.1016/j.imlet.2012.06.002.
7. Narendrakumar G.Dey R.Godavarthi SS.Preethi TV. Effect of Baculovirus with adjuvants against Helicoverpaarmigera (HBN) on Cotton and evaluation of its effect in Different Instar. Research Journal of Pharmacy and Technology. 2017; 10(7): 2111-2113. doi.org/10.5958/0974-360X.2017.00369.9.
8. Ananya KV.Patil AB. Gowda DV.Preethi S. Adjuvants employed in the Fabrication of sublingual vaccines. Research Journal of Pharmacy and Technology. 2020; 13(8): 3957-3962. doi.org/10.5958/0974-360X.2020.00700.3.
9. Chaudhary N.Weissman D. Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discovery. 2021; 20(11): 817–38. doi.org/10.1038/s41573-021-00283-5.
10. Jordan MB. Mills DM.Kappler J.Marrack P.Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004; 304: 1808–1810. doi.org/10.1126/science.1089926.
11. Evans JT.Cluff CW. Johnson DA. Lacy MJ. Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529. Expert Review of Vaccines (Second Edition). 2003; 2(2): 219–29. doi.org/10.1586/14760584.2.2.219.
12. Pouliot K.Buglione-Corbett R. Marty-Roix R.Montminy-Paquette S. West K. Wang S. Lu S. Lien E. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine. 2014; 32: 5049–5056.doi.org/10.1016/j.vaccine.2014.07.010.
13. Lilik M. Thomas VW.Nusdianto T.Suwarno.Koesnoto P. Nanda AN.Mahendra P.Zerlinda DA.Dita NP. Adjuvant Therapy of Syzygiumcumini Leaf and Fruit Extract Nanoparticles to Histopathological Changes of Mice Organ with Malaria. Research Journal of Pharmacy and Technology. 2022; 15(1): 389-394. doi.org/10.52711/0974-360X.2022.00064.
14. O’Hagan DT.Ott GS. De Gregorio E.Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012; 30:4341–4348. doi.org/10.1016/j.vaccine.2011.09.061.
15. O’Hagan DT.Ott GS. Nest GV.Rappuoli R.Giudice GD. The history of MF59 ((R)) adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines. 2013; 12: 13–30. doi.org/10.1586/erv.12.140.
16. O’Hagan DT.Rappuoli R. De Gregorio E. Tsai T. Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Review of Vaccines. 2011; 10:447–462. doi.org/10.1586/erv.11.23.
17. Cioncada R. Maddaluno M. Vo HTM. Woodruff M.Tavarini S.Sammicheli C.Tortoli M.Pezzicoli A. De Gregorio E. Carroll MC. et al. Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. PLoS One. 2017; 12: e0185843. doi.org/10.1371/journal.pone.0185843
18. Ko EJ, Lee YT. Kim KH. Jung YJ. Lee Y. Denning TL. Kang SM. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells. Journal of Virology. 2016; 90: 6976–6988. doi.org/10.1128/JVI.00339-16.
19. Nakaya HI. Clutterbuck E.Kazmin D. Wang L.Cortese M.Bosinger SE. Patel NB. Zak DE.Aderem A. Dong T.et al. Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci U S A. 2016; 113: 1853–1858. doi.org/10.1073/pnas.1519690113.
20. Chowdhury M. Kumar DP.Sekhar HM. Exploration of Basella alba mucilage as a novel adjuvant in Pharmaceutical Formulation. Research Journal of Pharmacy Technology. 2022; 15(6): 2609-2615. doi.org/10.52711/0974-360X.2022.00436.
21. Didierlaurent AM.Laupèze B. Di Pasquale A.Hergli N.Collignon C.Garçon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017; 16: 55–63. doi.org/10.1080/14760584.2016.1213632.
22. Leroux-Roels G.Leroux-Roels I. Clement F.Ofori-Anyinam O.Lievens M.Jongert E.Moris P. Ballou WR. Cohen J. Evaluation of the immune response to RTS, S/AS01 and RTS, S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults. Human Vaccines and Immunotherapeutics. 2014; 10: 2211–2219. doi.org/10.4161/hv.29375.
23. Morel S.Didierlaurent A. Bourguignon P.Delhaye S.Baras B. Jacob V.Planty C, Elouahabi A.Harvengt P.Carlsen H et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29: 2461–2473. doi.org/10.1016/j.vaccine.2011.01.011.
24. Lokhande SS. Microemulsions as Promising Delivery Systems: A Review. Asian Journal of Pharmaceutical Research.2019; 9(2): 90-96. doi.org/10.5958/2231-5691.2019.00015.7.
25. Garcon N et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs. 2011; 25: 217–226. doi.org/10.2165/11591760-000000000-00000.
26. Skinner SR. et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccines for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016; 15: 367–387. doi.org/10.1586/14760584.2016.1124763.
27. Naud PS. et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Human Vaccines and Immunotherapeutics. 2014; 10: 2147–2162. doi.org/10.4161/hv.29532.
28. Maskare RG.Indurwade NH.Deshmukh RA.Kuthe PV.Londhe PM.Deshmukh MT. Nanoemulsions: Increasing Possibilities in Oral Drug Delivery. Asian Journal of Pharmacy and Technology. 2021; 11(1):53-58.doi.org/10.5958/2231-5713.2021.00009.X.
29. Guiducci C et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006; 203: 1999–2008. doi.org/10.1084/jem.20060401
30. Hartmann G. Nucleic acid immunity. Adv Immunol. 2017; 133: 121–169.doi.org/10.1016/bs.ai.2016.11.001.
31. Kyriakidis NC. Lopez-Cortes A. Gonzalez EV.Grimaldos AB. Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021; 6(1):1–17. doi.org/10.1038/s41541-021-00292-w.